Den europeiske union - norsk - EMA (European Medicines Agency)

bavarian nordic a/s - vibrio cholerae, belastning cvd 103-hgr, live - kolera - vaksiner - vaxchora is indicated for active immunisation against disease caused by vibrio cholerae serogroup o1 in adults and children aged 2 years and older. denne vaksinen skal brukes i samsvar med offisielle anbefalinger.

Den europeiske union - norsk - EMA (European Medicines Agency)

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vaksiner - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. bruk av denne vaksinen skal være i samsvar med offisielle anbefalinger.

Den europeiske union - norsk - EMA (European Medicines Agency)

janssen-cilag international nv - adenovirus type 26 encoding the sars-cov-2 spike glycoprotein (ad26.cov2-s) - covid-19 virus infection - vaksiner - jcovden is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 years of age and older. bruk av denne vaksinen skal være i samsvar med offisielle anbefalinger.

Den europeiske union - norsk - EMA (European Medicines Agency)

astrazeneca ab - chadox1-sars-cov-2 - covid-19 virus infection - vaksiner - vaxzevria is indicated for active immunisation to prevent covid 19 caused by sars cov 2, in individuals 18 years of age and older. bruk av denne vaksinen skal være i samsvar med offisielle anbefalinger.

Den europeiske union - norsk - EMA (European Medicines Agency)

sanofi pasteur - sars-cov-2 prefusion spike delta tm protein, recombinant (b.1.351 strain) - covid-19 virus infection - vaksiner - vidprevtyn beta is indicated as a booster for active immunisation to prevent covid-19 in adults who have previously received an mrna or adenoviral vector covid-19 vaccine (see sections 4. 2 og 5. 1 in product information document). bruk av denne vaksinen skal være i samsvar med offisielle anbefalinger.

Den europeiske union - norsk - EMA (European Medicines Agency)

pfizer europe ma eeig - respiratory syncytial virus, subgroup a, stabilized prefusion f protein / respiratory syncytial virus, subgroup b, stabilized prefusion f protein - respiratorisk syncytialvirusinfeksjoner - vaksiner - abrysvo is indicated for:passive protection against lower respiratory tract disease caused by respiratory syncytial virus (rsv) in infants from birth through 6 months of age following maternal immunisation during pregnancy. se avsnitt 4. 2 og 5. active immunisation of individuals 60 years of age and older for the prevention of lower respiratory tract disease caused by rsv. bruk av denne vaksinen skal være i samsvar med offisielle anbefalinger.

Den europeiske union - norsk - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - modifisert levende bovin viral diarévirus type 1, ikke-cytopatisk stamme ke-9 og modifisert levende virus diarrévirus type 2, ikke-cytopatisk stamme ny-93 - immunologicals for bovidae, live viral vaksiner - for aktive vaksinering av storfe fra 3 måneders alder for å redusere hypertermi og for å minske reduksjonen av leukocyte count forårsaket av bovine virus diaré virus (bvdv-1 og bvdv-2), og for å redusere virus shedding og viraemia forårsaket av bvdv-2. for aktiv immunisering av storfe mot bvdv-1 og bvdv-2, for å forhindre fødsel av vedvarende infiserte kalver forårsaket av transplacental infeksjon.

Den europeiske union - norsk - EMA (European Medicines Agency)

bavarian nordic a/s - modifisert vaccinia ankara - bavarian nordic (mva-bn) virus - smallpox vaccine; monkeypox virus - andre viral vaksiner, - active immunisation against smallpox, monkeypox and disease caused by vaccinia virus in adults (see sections 4. 4 og 5. bruk av denne vaksinen skal være i samsvar med offisielle anbefalinger.

Den europeiske union - norsk - EMA (European Medicines Agency)

ceva santé animale - inaktivert coxiella burnetii-vaksine, stamme nine mile - immunologicals for bovidae, inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia) - goats; cattle - cattle: , for the active immunisation of cattle to lower the risk for non-infected animals vaccinated when non-pregnant to become shedder (5 times lower probability in comparison with animals receiving a placebo), and to reduce shedding of coxiella burnetii in these animals via milk and vaginal mucus. , onset of immunity: not established. , duration of immunity: 280 days after completion of the primary vaccination course. , goats: , for the active immunisation of goats to reduce abortion caused by coxiella burnetii and to reduce shedding of the organism via milk, vaginal mucus, faeces and placenta. , onset of immunity: not established. , duration of immunity: one year after completion of the primary vaccination course.

Den europeiske union - norsk - EMA (European Medicines Agency)

laboratorios hipra, s.a. - inactivated rabbit haemorrhagic disease type 2 virus (rhdv2), strainv-1037 - inaktivert viral vaksiner - kaniner - for aktive vaksinering av kaniner fra en alder av 30 dager for å redusere dødelighet forårsaket av kanin blødningssykdom type 2-viruset (rhdv2).